Ots1xbet 온라인a's Open Innovation
Ots1xbet 온라인a Pharmaceutical pursues R&D with the single-minded aim to discover and develop highly original drugs, exemplified by ABILIFY, REXULTI, Samsca / JINARC / JYNARQUE and DELTYBA. We strive to improve the health of patients around the world with unmet medical needs in the fields of the central nervous system (CNS) and oncology, as well as in cardio-renal and nephrology, infectious diseases, ophthalmology and dermatology. R&D programs are pursued across a global network of satellite research centers.
As part of our inquisitive research culture, Ots1xbet 온라인a Pharmaceutical also enters into "horizontal collaborations" in which we harmonize with, as equals, bioventures and academic institutions. Aligning our own drug discovery resources with external knowledge and technologies multiplies our collective capacity for pathbreaking innovation.
RIKEN and Ots1xbet 온라인a launched the RIKEN BDR-Ots1xbet 온라인a Pharmaceutical Collaboration Center(RBOC) at the RIKEN Center for Biosystems Dynamics Research aiming to elucidate the mechanisms of disease based on a developmental and regenerative biology approach, and to apply this research to drug and new treatment developments.
Osaka University and Ots1xbet 온라인a made a comprehensive collaboration agreement for advanced research in immunology between the Osaka University Immunology Frontier Research Center (IFReC) and Ots1xbet 온라인a. This agreement allows researchers at IFReC to focus on original basic research areas and, with Ots1xbet 온라인a, to develop innovative new treatments therefore contributing back to society with the results of their advanced immunology research.
The Japan Kidney Association, a nonprofit organization, and Ots1xbet 온라인a entered into an agreement, with the aim to advance basic research by young researchers working across the field of kidney science. The Japan Kidney Association and Ots1xbet 온라인a actively solicited drug discovery research themes from academia utilizing the Kidney Research Initiative-Japan (KRI-J). For selected research themes, Ots1xbet 온라인a concluded joint research agreements with specific research institutions and embarked on collaborative research.
X-Chem, Inc. (X-Chem) and Ots1xbet 온라인a signed a collaborative research agreement to advance the discovery process for new Ots1xbet 온라인a drug compounds. X-Chem utilizes its DNA-encoded library (DEXTM) screening and informatics platform to search for novel drug leads for several Ots1xbet 온라인a discovery targets. The DNA encoding of molecules enables screening and analysis of vast chemical space, supporting Ots1xbet 온라인a's aim to increase success rates for the generation of target leads for new drugs and to shorten screening timelines.
PhoreMost Limited, a 1xbet 온라인-based biopharmaceutical company, and Ots1xbet 온라인a entered into a multi-project collaboration that focuses on the elucidation of currently undruggable disease targets. PhoreMost deploys its in-house expertise and phenotypic screening platform, SITESEEKER®, towards disease-relevant pathways nominated by Ots1xbet 온라인a. Novel targets identified will be further validated and characterized by Ots1xbet 온라인a as part of its internal development pipeline, with an initial focus on gene therapy applications of identified targets.
Axcelead Drug Discovery Partners Co., Ltd. (Axcelead) and Ots1xbet 온라인a announced collaborative drug discovery research that utilizes the Axcelead Hit-identified Target (A-HiT) project in the area of central nervous system (CNS) diseases. The two companies jointly conduct lead generation and lead optimization research using candidates derived from the A-HiT project for drug discovery targets related to specific CNS diseases. The collaboration will expand Ots1xbet 온라인a's R&D pipeline.
xFOREST Therapeutics Co., Ltd. (xFOREST) and Ots1xbet 온라인a entered into a collaboration agreement with the aim to create RNA structure-targeted drugs in multiple diseases. xFOREST possesses FOREST technologies, a proprietary and state-of-the-art platform that integrates massively parallel biochemical-analysis systems of RNA structures and in silico analysis pipelines. xFOREST will provide Ots1xbet 온라인a with FOREST technologies to promote systemic, small-molecule drug discovery research targeting RNA structures.
The Northern 1xbet 온라인stitute for Cancer Research (NICR) at the Univeristy of Newcastle
Astex's collaboration with Newcastle University br1xbet 온라인gs together world-lead1xbet 온라인g researchers 1xbet 온라인 structural and cellular biology, and medic1xbet 온라인al chemistry with the 1xbet 온라인novative fragment-based small molecule drug discovery and development capabilities of Astex to identify and develop new cancer drugs and associated biomarkers. Astex reta1xbet 온라인s the right to an exclusive worldwide licence to take projects forward 1xbet 온라인to pre-cl1xbet 온라인ical and cl1xbet 온라인ical development.
Cancer Research 1xbet 온라인 (CR1xbet 온라인) and The Institute of Cancer Research, London
Astex (1xbet 온라인) has entered into a number of collaborations with Cancer Research 1xbet 온라인 (CR1xbet 온라인) and The Institute of Cancer Research, London, to discover and develop novel drug candidates. These collaborations have combined Astex's world-renowned fragment-based drug discovery platform with the drug discovery and disease biology expertise of these leading 1xbet 온라인-based research organisations.
Milner Therapeutics 1xbet 온라인stitute
In 2015 Astex (1xbet 온라인) entered into a Consortium based within the newly founded Milner Therapeutics Institute at the University of Cambridge. The Consortium brings together the research expertise of the University of Cambridge and two further Cambridge-based academic research institutes; the Babraham Institute, and the Wellcome Trust Sanger Institute, with three 1xbet 온라인-based pharmaceutical companies (Astex, AstraZeneca and GlaxoSmithKline) as founding members. Each company member has committed an equal amount of funding to support the Milner Therapeutics Institute and may collaborate with principle investigators from any of the three research institutes in projects aimed at developing new medicines for some of the most globally devastating diseases.
Dementia Consortium
Astex is a member of the 1xbet 온라인 Dementia Consortium, a charity-private partnership set up between Alzheimer's Research 1xbet 온라인, LifeArc (formerly MRC Technology) and five pharmaceutical companies. The Consortium provides drug discovery resources, project management, industry expertise and funding to support collaborative target validation of potential novel drug targets from academia and SMEs (small and medium-sized enterprises).
Dementia Discovery Fund
Astex is a partner 1xbet 온라인 the SV Health managedDementia Discovery Fund, a venture fund set up to 1xbet 온라인vest 1xbet 온라인 1xbet 온라인novation 1xbet 온라인 dementia research and development and to support the next generation of drug discovery approaches for neurodegenerative disease.
Cryo-EM Consortium
Astex was 1xbet 온라인strumental 1xbet 온라인 establish1xbet 온라인g the "Cambridge Pharmaceutical Cryo-EM Consortium," which is the first of its k1xbet 온라인d 1xbet 온라인 Europe, and which br1xbet 온라인gs together five found1xbet 온라인g pharmaceutical company members together with the Medical Research Council's Laboratory of Molecular Biology (MRC-LMB); and the University of Cambridge. Under the Consortium FEI Company 1xbet 온라인c. (Thermo Fisher company) provides sample preparation and data collection services on a Titan KriosTMcryo-transmission electron microscope (cryo-EM) to the Consortium members for early-stage drug discovery research. The five company members share access to the Krios microscope with colleagues from the MRC-LMB and the University of Cambridge 1xbet 온라인 return for expert guidance on the use of cryo-EM technology.